Although we demonstrated the vedolizumab specificity of this 4-gene panel as compared with anti-TNF treated patients, the predictive accuracy in ustekinumab- or tofacitinib-treated patients is currently unknown. Furthermore, the rather limited sample size in this pilot project warrants caution. However...